ReviewCureus2025
Efficacy and Safety of Lorundrostat in Patients With Uncontrolled and Treatment-Resistant Hypertension: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis evaluated the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor, in patients with uncontrolled or treatment-resistant hypertension. A comprehensive literature search was conducted across major electronic databases, including MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and Scopus through July 25, 2025. Randomized controlled trials comparing lorundrostat to placebo in adult patients with uncontrolled hypertension were included. Three studies met the inclusion criteria and were analyzed using Review Manager 5.4.1 (The Cochrane Collaboration, London, England, UK) with random-effects models. The pooled analysis demonstrated that lorundrostat achieved a statistically significant reduction in systolic blood pressure of 8.04 mmHg compared to placebo (95% confidence interval (CI): -10.69 to -5.39) with low heterogeneity (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.